Eteplirsen's Global Approval Status
Eteplirsen (Exondys 51), developed by Sarepta Therapeutics for Duchenne muscular dystrophy (DMD) with exon 51 skipping mutations, received accelerated FDA approval in the United States in 2016 based on increased dystrophin production.[1] No regulatory agency outside the US has granted marketing authorization for eteplirsen as of the latest available data.
Has Japan Approved Eteplirsen?
Japan's Ministry of Health, Labour and Welfare (MHLW) rejected eteplirsen in 2018 after review by the Pharmaceuticals and Medical Devices Agency (PMDA). The rejection cited insufficient evidence of clinical benefit beyond surrogate endpoints like dystrophin levels.[2]
What About Europe?
The European Medicines Agency (EMA) issued a negative opinion in 2018, recommending against approval. The Committee for Medicinal Products for Human Use (CHMP) found the dystrophin increase too small and inconsistent to justify benefits outweighing risks.[3] Sarepta withdrew its application later that year without resubmission.
Approvals in Other Countries?
No approvals exist in Canada, Australia, Brazil, South Korea, or other major markets. Health Canada denied orphan drug status in 2017 due to unresolved safety concerns.[4] Sarepta's global filings have largely stalled post-US approval, focusing instead on next-generation drugs like golodirsen (Vyondys 53, US-only).
Why Limited Global Approvals?
Regulators outside the US demand stronger evidence of functional improvements (e.g., muscle strength, walking ability) rather than relying solely on biomarkers. Ongoing confirmatory trials, like Study 4053-101 (NCT02255552), aim to address this but have not yet swayed international agencies.[1][5]
[1]: FDA Approval Summary for Eteplirsen
[2]: PMDA Review Report (Japanese)
[3]: EMA Assessment Report
[4]: Health Canada Decision Summary
[5]: ClinicalTrials.gov - Study 4053-101